Palmoplantar psoriasis (PP) is a chronic, treatment-resistant form of psoriasis that affects the palms and soles, often leading to significant discomfort, functional impairment, and reduced quality of life. For years, patients and dermatologists have sought effective, safe therapies to manage this stubborn condition—and emerging research points to 308-nm monochromatic excimer light (MEL) as a promising solution. Let’s dive into the science behind this innovative treatment, backed by key clinical studies.

What Makes 308-nm MEL Unique?

Unlike broad-spectrum phototherapies, 308-nm MEL delivers a targeted, monochromatic beam of ultraviolet light that zeroes in on psoriatic lesions while sparing surrounding healthy tissue (Gattu et al., 2009). This selectivity is a game-changer: it allows dermatologists to adjust dosages precisely based on skin type and lesion response, minimizing side effects and maximizing therapeutic impact. Derived from xenon-chloride excimers, this light targets the immune cells and abnormal keratinocyte proliferation that drive psoriasis, offering a focused alternative to traditional treatments like narrow-band UVB (NB-UVB) or PUVA therapy (Nisticò et al., 2006).

Clinical Efficacy: The Evidence Speaks

Numerous studies have validated 308-nm MEL’s effectiveness for palmoplantar psoriasis, with consistent improvements in clearance and symptom reduction.

In a landmark study by Nisticò et al. (2006), 54 patients with PP underwent MEL treatments every 7–14 days for a mean of 10 sessions, with dosages adjusted for skin type and response. After 4 months, the results were striking: 31 patients (57.4%) achieved complete remission, 13 (24.1%) had partial remission, and 10 (18.5%) experienced moderate improvement. All patients completed the treatment, highlighting its tolerability and feasibility for long-term use.

A 2008 study by Han et al. further confirmed these findings, comparing MEL’s efficacy across psoriasis vulgaris and palmoplantar psoriasis. For PP patients (n=15) treated once weekly for 25 sessions, the mean severity index score improved by 52.5%, with the therapy well-tolerated and minimal side effects (Han et al., 2008). While complete clearance (6.7%) was lower than in psoriasis vulgaris, the consistent improvement underscored MEL’s value for this hard-to-treat subtype.

Notably, 308-nm MEL performs comparably to established therapies like cream PUVA—without the need for pre-treatment drug application. In a randomized controlled trial by Neumann et al. (2006), 10 PP patients received cream PUVA on one side and 308-nm MEL on the other. After 5 weeks, both treatments yielded nearly identical PASI score reductions: 63.57% for MEL and 64.64% for cream PUVA. The real advantage? MEL avoided the need for topical photosensitizers, reducing the risk of adverse reactions and improving patient compliance. Even after 12 weeks of follow-up, only one patient experienced a relapse, demonstrating sustained benefits.

Safety and Tolerability: A Key Advantage

One of 308-nm MEL’s greatest strengths is its favorable safety profile. Clinical trials consistently report low incidence of side effects, which are typically mild and transient. Han et al. (2008) noted pruritus, erythema, and occasional blister formation—symptoms that resolved without additional intervention. Neumann et al. (2006) observed only mild skin irritation in a few patients, with no severe adverse events. This safety record makes MEL an attractive option for patients who cannot tolerate more aggressive treatments or who experience side effects with PUVA or systemic therapies.

How Does MEL Compare to Other Treatments?

When pitted against NB-UVB, 308-nm MEL offers distinct advantages. Gattu et al. (2009) reviewed 18 clinical trials and concluded that MEL’s selectivity allows for higher, more targeted dosages, potentially making it more effective than non-selective NB-UVB. Unlike PUVA, MEL does not require pre-treatment with psoralens, eliminating the risk of drug-related side effects and simplifying the treatment process (Neumann et al., 2006). For palmoplantar psoriasis—where thickened skin can reduce the penetration of topical therapies—MEL’s focused light delivery ensures optimal tissue penetration and therapeutic effect.

Who Can Benefit from 308-nm MEL?

308-nm MEL is particularly well-suited for patients with mild-to-moderate palmoplantar psoriasis who have not responded to topical treatments or who seek a non-systemic alternative (Han et al., 2008). It is also ideal for patients who prioritize convenience: treatments are relatively quick, require no pre-medication, and have minimal downtime. While large-scale, long-term trials are still needed to confirm MEL’s durability (Gattu et al., 2009), existing data supports its use as a first-line or adjunctive therapy for PP.

The Future of Palmoplantar Psoriasis Treatment

As research continues to evolve, 308-nm monochromatic excimer light stands out as a safe, effective, and patient-centric option for palmoplantar psoriasis. Its targeted approach, comparable efficacy to established therapies, and low side effect profile make it a valuable tool in the dermatologist’s arsenal. For patients living with the daily challenges of PP, MEL offers a path to clearer skin and improved quality of life—without the trade-offs of more invasive treatments.

References

1. Gattu, S., Rashid, R. M., & Wu, J. J. (2009). 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. Journal of the European Academy of Dermatology and Venereology, 23(1), 36–41. https://doi.org/10.1111/j.1468-3083.2008.02942.x
2. Han, L., Somani, A.-K., Huang, Q., Fang, X., Jin, Y., Xiang, L.-H., & Zheng, Z.-Z. (2008). Evaluation of 308-nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis. Photodermatology, Photoimmunology & Photomedicine, 24(5), 231–236. https://doi.org/10.1111/j.1600-0781.2008.00364.x
3. Nisticò, S. P., Saraceno, R., Stefanescu, S., & Chimenti, S. (2006). A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis. Journal of the European Academy of Dermatology and Venereology, 20(5), 523–526. https://doi.org/10.1111/j.1468-3083.2006.01503.x
4. Neumann, N. J., Mahnke, N., Korpusik, D., Stege, H., & Ruzicka, T. (2006). Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA. Acta Dermato-Venereologica, 86(1), 22–24. https://doi.org/10.2340/00015555-0002